Edition:
United States

Neptune Technologies & Bioressources Inc (NEPT.PH)

NEPT.PH on Philadelphia Stock Exchange

1.10USD
19 Jan 2017
Change (% chg)

$0.03 (+2.80%)
Prev Close
$1.07
Open
$1.10
Day's High
$1.10
Day's Low
$1.10
Volume
100
Avg. Vol
6,468
52-wk High
$1.50
52-wk Low
$0.91

Latest Key Developments (Source: Significant Developments)

Acasti Pharma Q3 loss C$0.22/shr
Thursday, 12 Jan 2017 05:15pm EST 

Acasti Pharma Inc : Acasti Pharma reports third quarter 2017 financial results . Q3 loss per share C$0.22 . Acasti pharma - Had cash,short-term investments of $5.8 million as of Nov 30, 2016 .Acasti Pharma - if co doesn't raise additional funds, there exists material uncertainty casting substantial doubt about ability to continue as going concern.  Full Article

Acasti Pharma announces proposed offering of units
Monday, 5 Dec 2016 05:38pm EST 

Acasti Pharma Inc : Acasti Pharma announces proposed offering of units .Acasti Pharma-Received receipt for a preliminary short form prospectus for minimum gross proceeds of CAD$6.5 million, maximum gross proceeds of CAD$10 million.  Full Article

Enzymotec qtrly non-gaap earnings per share $0.03
Wednesday, 16 Nov 2016 07:30am EST 

Enzymotec Ltd : Enzymotec - Qtrly net revenues decreased 8.2% and 2.7% to $11.4 million, compared to Q3 of 2015 and Q2 of 2016, respectively . Enzymotec Ltd. reports third quarter 2016 unaudited financial results . Q3 non-gaap earnings per share $0.03 . Q3 gaap loss per share $0.01 . Q3 earnings per share view $0.07 -- Thomson Reuters I/B/E/S . Sees FY 2016 non-gaap earnings per share $0.17 to $0.19 . Sees FY 2016 revenue $47.5 million to $49.5 million . Enzymotec-On April 27, 2014,Neptune Technologies & Bioresources,Co entered into settlement agreement under which all civil actions against co dismissed .On November 2, 2016, Neptune sent company a notice of default and termination in respect of settlement agreement.  Full Article

Neptune and Ingenutra signs exclusive worldwide agreement for MaxSimil
Friday, 7 Oct 2016 08:07am EDT 

Neptune Technologies & Bioressources Inc : Terms also cover potential collaboration between both companies on clinical trials . Neptune Technologies & Bioressources Inc says all other terms of agreement remain confidential . Neptune and Ingenutra sign an exclusive worldwide agreement for Maxsimil . All other terms of agreement remain confidential. . Agreement allows neptune to manufacture, distribute and sell Maxsimil in nutraceutical field worldwide .Says agreement is valid till 2028.  Full Article

Richard Schottenfeld reports 5.4 pct stake in Neptune Technologies & Bioressources
Friday, 22 Jul 2016 04:10pm EDT 

Neptune Technologies & Bioressources Inc : Richard Schottenfeld Reports 5.4 Pct Stake In Neptune Technologies & Bioressources Inc As Of July 12 - SEC filing .Acquired shares of Neptune Technologies common stock believing that such shares of common stock were undervalued.  Full Article

Acasti posts qtrly loss per share of $0.29
Monday, 11 Jul 2016 05:30pm EDT 

Acasti Pharma Inc: Acasti announces first quarter results .Qtrly loss per share $0.29.  Full Article

Neptune announces Q1 results
Monday, 11 Jul 2016 05:30pm EDT 

Neptune Technologies & Bioressources Inc :Neptune announces first quarter results.  Full Article

Neptune Technologies & Bioressources qtrly revenues $11.3 mln
Monday, 11 Jul 2016 05:24pm EDT 

Neptune Technologies & Bioressources Inc : Neptune Technologies & Bioressources Inc qtrly revenues reached $11.3 million, up 270% versus last year . Revised revenue guidance for fiscal 2017 to over $43 million, continue to expect double-digit adjusted ebitda margin for 2017 . Qtrly loss per share $0.03 . Consolidated cash, short term investments were $14.6 million as at may 31, 2016, with $9.6 million for co's unit acasti .If acasti doesn't raise funds, exists material uncertainty that casts doubt about acasti’s ability to continue as going concern.  Full Article

Neptune Technologies & Bioressources reports Q4 revenue of $10 mln
Wednesday, 25 May 2016 05:00pm EDT 

Neptune Technologies & Bioressources Inc : Neptune announces fourth quarter and fiscal year results . Neptune Sees FY 2017 revenue for Nutraceutical Segment to be greater than last 12 month fiscal 2016 revenue proforma of $41 million . Neptune Technologies & Bioressources Inc Qtrly revenues of $10.0 million, up 161% versus last year . In fiscal 2017, we expect significant growth in revenues and adjusted ebitda for nutraceutical segment .Net loss was $379,000 for current quarter, versus a net loss of $10.7 million in prior year.  Full Article

Acasti Pharma says Jan D'Alvise named as CEO
Thursday, 12 May 2016 08:08am EDT 

Acasti Pharma Inc : Says Jan D'Alvise appointed as president and chief executive officer effective June 1, 2016 .Jan D'Alvise appointed president & CEO of Acasti Pharma.  Full Article